|
AU756490B2
(en)
|
1997-08-26 |
2003-01-16 |
Abgenix, Inc. |
A process for inhibiting complement activation via the alternative pathway
|
|
US7959919B2
(en)
|
2003-11-19 |
2011-06-14 |
Novelmed Therapeutics, Inc. |
Method of inhibiting factor B-mediated complement activation
|
|
US7423128B2
(en)
*
|
2004-11-03 |
2008-09-09 |
Amgen Fremont Inc. |
Anti-properdin antibodies, and methods for making and using same
|
|
US9745367B2
(en)
|
2007-03-23 |
2017-08-29 |
Novelmed Theraputics, Inc. |
Alternative pathway specific antibodies for treating arthritis
|
|
US8192742B2
(en)
|
2007-03-23 |
2012-06-05 |
NovelMed Therapeutics |
Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
|
|
CA2685208C
(en)
|
2007-04-24 |
2014-04-08 |
Novelmed Therapeutics, Inc. |
Methods and compositions of inhibiting complement and cellular activation with dextran sulfate
|
|
US10131706B2
(en)
|
2007-08-27 |
2018-11-20 |
Novelmed Therapeutics, Inc. |
Anti-factor Bb antibodies
|
|
US8981060B2
(en)
|
2007-08-27 |
2015-03-17 |
Novelmed Therapuetics, Inc. |
Method of inhibiting complement activation with factor Bb specific antibodies
|
|
DK2262831T3
(en)
|
2008-03-03 |
2015-04-27 |
Novelmed Therapeutics Inc |
ANTI-Properdin ANTIBODIES
|
|
US20140127204A1
(en)
|
2010-09-03 |
2014-05-08 |
Novelmed Therapeutics, Inc. |
Anti-properdin antibodies
|
|
US8664362B2
(en)
|
2008-03-03 |
2014-03-04 |
NovelMed Therapeutics |
Humanized and chimeric anti-properdin antibodies
|
|
EP2544694B1
(en)
*
|
2010-03-02 |
2018-10-31 |
Novelmed Therapeutics, Inc. |
A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit c5 interactions with properdin
|
|
EP2545075B1
(en)
*
|
2010-03-10 |
2020-07-01 |
NovelMed Therapeutics, Inc. |
Humanized and chimeric anti-properdin antibodies
|
|
WO2013102123A2
(en)
|
2011-12-28 |
2013-07-04 |
Novelmed Therapeutics, Inc. |
Aglycosylated human antibody and fusion protein and uses thereof
|
|
US9243070B2
(en)
|
2012-04-03 |
2016-01-26 |
Novelmed Therapeutics, Inc. |
Humanized and chimeric anti-factor Bb antibodies and uses thereof
|
|
AU2013243574B2
(en)
|
2012-04-03 |
2017-12-07 |
Novelmed Therapeutics, Inc |
Humanized and chimeric anti-factor C3 antibodies and uses thereof
|
|
US9926366B2
(en)
|
2012-10-04 |
2018-03-27 |
Novelmed Therapeutics, Inc. |
Methods of treating a hemolytic disorder comprising administering anti-properdin antibodies
|
|
EP3086809A4
(en)
|
2013-12-24 |
2017-11-29 |
NovelMed Therapeutics, Inc. |
Compositions and methods of treating ocular diseases
|
|
KR20190112299A
(ko)
*
|
2017-01-27 |
2019-10-04 |
울트라휴먼 원 리미티드 |
결합제
|
|
KR20260069620A
(ko)
|
2017-01-30 |
2026-05-15 |
알렉시온 파마슈티칼스, 인코포레이티드 |
1가 항-프로페르딘 항체 및 항체 단편
|
|
GB201803745D0
(en)
*
|
2018-03-08 |
2018-04-25 |
Ultrahuman Eight Ltd |
PD1 binding agents
|
|
GB201804860D0
(en)
*
|
2018-03-27 |
2018-05-09 |
Ultrahuman Two Ltd |
CD47 Binding agents
|